Literature DB >> 28684146

Physiologically based pharmacokinetic modeling of human exposure to perfluorooctanoic acid suggests historical non drinking-water exposures are important for predicting current serum concentrations.

Rachel Rogers Worley1, Xiaoxia Yang2, Jeffrey Fisher3.   

Abstract

Manufacturing of perfluorooctanoic acid (PFOA), a synthetic chemical with a long half-life in humans, peaked between 1970 and 2002, and has since diminished. In the United States, PFOA is detected in the blood of >99% of people tested, but serum concentrations have decreased since 1999. Much is known about exposure to PFOA in drinking water; however, the impact of non-drinking water PFOA exposure on serum PFOA concentrations is not well characterized. The objective of this research is to apply physiologically based pharmacokinetic (PBPK) modeling and Monte Carlo analysis to evaluate the impact of historic non-drinking water PFOA exposure on serum PFOA concentrations. In vitro to in vivo extrapolation was utilized to inform descriptions of PFOA transport in the kidney. Monte Carlo simulations were incorporated to evaluate factors that account for the large inter-individual variability of serum PFOA concentrations measured in individuals from North Alabama in 2010 and 2016, and the Mid-Ohio River Valley between 2005 and 2008. Predicted serum PFOA concentrations were within two-fold of experimental data. With incorporation of Monte Carlo simulations, the model successfully tracked the large variability of serum PFOA concentrations measured in populations from the Mid-Ohio River Valley. Simulation of exposure in a population of 45 adults from North Alabama successfully predicted 98% of individual serum PFOA concentrations measured in 2010 and 2016, respectively, when non-drinking water ingestion of PFOA exposure was included. Variation in serum PFOA concentrations may be due to inter-individual variability in the disposition of PFOA and potentially elevated historical non-drinking water exposures. Published by Elsevier Inc.

Entities:  

Keywords:  Human; Monte Carlo; PBPK; PFOA

Mesh:

Substances:

Year:  2017        PMID: 28684146      PMCID: PMC5664934          DOI: 10.1016/j.taap.2017.07.001

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  76 in total

1.  Lognormal distributions for body weight as a function of age for males and females in the United States, 1976-1980.

Authors:  D E Burmaster; E A Crouch
Journal:  Risk Anal       Date:  1997-08       Impact factor: 4.000

2.  Perfluorooctanoic acid exposure and pregnancy outcome in a highly exposed community.

Authors:  David A Savitz; Cheryl R Stein; Scott M Bartell; Beth Elston; Jian Gong; Hyeong-Moo Shin; Gregory A Wellenius
Journal:  Epidemiology       Date:  2012-05       Impact factor: 4.822

3.  Comparative pharmacokinetics of perfluorononanoic acid in rat and mouse.

Authors:  Katoria Tatum-Gibbs; John F Wambaugh; Kaberi P Das; Robert D Zehr; Mark J Strynar; Andrew B Lindstrom; Amy Delinsky; Christopher Lau
Journal:  Toxicology       Date:  2011-01-13       Impact factor: 4.221

4.  Perfluorooctanoic acid, perfluorooctanesulfonate, and serum lipids in children and adolescents: results from the C8 Health Project.

Authors:  Stephanie J Frisbee; Anoop Shankar; Sarah S Knox; Kyle Steenland; David A Savitz; Tony Fletcher; Alan M Ducatman
Journal:  Arch Pediatr Adolesc Med       Date:  2010-09

5.  Metabolic Handling of perfluorooctanoic acid in rats.

Authors:  R H Ophaug; L Singer
Journal:  Proc Soc Exp Biol Med       Date:  1980-01

6.  Rate of decline in serum PFOA concentrations after granular activated carbon filtration at two public water systems in Ohio and West Virginia.

Authors:  Scott M Bartell; Antonia M Calafat; Christopher Lyu; Kayoko Kato; P Barry Ryan; Kyle Steenland
Journal:  Environ Health Perspect       Date:  2010-02       Impact factor: 9.031

7.  Roles of organic anion transporters in the renal excretion of perfluorooctanoic acid.

Authors:  Hatsuki Nakagawa; Taku Hirata; Tomohiro Terada; Promsuk Jutabha; Daisaku Miura; Kouji H Harada; Kayoko Inoue; Naohiko Anzai; Hitoshi Endou; Ken-Ichi Inui; Yoshikatsu Kanai; Akio Koizumi
Journal:  Basic Clin Pharmacol Toxicol       Date:  2008-07-01       Impact factor: 4.080

8.  Fluorotelomer alcohol biodegradation yields poly- and perfluorinated acids.

Authors:  Mary Joyce A Dinglasan; Yun Ye; Elizabeth A Edwards; Scott A Mabury
Journal:  Environ Sci Technol       Date:  2004-05-15       Impact factor: 9.028

9.  Perfluorooctanoic acid (PFOA) exposures and incident cancers among adults living near a chemical plant.

Authors:  Vaughn Barry; Andrea Winquist; Kyle Steenland
Journal:  Environ Health Perspect       Date:  2013-09-05       Impact factor: 9.031

10.  The C8 health project: design, methods, and participants.

Authors:  Stephanie J Frisbee; A Paul Brooks; Arthur Maher; Patsy Flensborg; Susan Arnold; Tony Fletcher; Kyle Steenland; Anoop Shankar; Sarah S Knox; Cecil Pollard; Joel A Halverson; Verónica M Vieira; Chuanfang Jin; Kevin M Leyden; Alan M Ducatman
Journal:  Environ Health Perspect       Date:  2009-07-13       Impact factor: 9.031

View more
  8 in total

1.  Perfluorinated Chemicals as Emerging Environmental Threats to Kidney Health: A Scoping Review.

Authors:  John W Stanifer; Heather M Stapleton; Tomokazu Souma; Ashley Wittmer; Xinlu Zhao; L Ebony Boulware
Journal:  Clin J Am Soc Nephrol       Date:  2018-09-13       Impact factor: 8.237

Review 2.  Challenges Associated With Applying Physiologically Based Pharmacokinetic Modeling for Public Health Decision-Making.

Authors:  Yu-Mei Tan; Rachel R Worley; Jeremy A Leonard; Jeffrey W Fisher
Journal:  Toxicol Sci       Date:  2018-04-01       Impact factor: 4.849

3.  Per- and polyfluoroalkyl substances and kidney function: Follow-up results from the Diabetes Prevention Program trial.

Authors:  Pi-I D Lin; Andres Cardenas; Russ Hauser; Diane R Gold; Ken P Kleinman; Marie-France Hivert; Antonia M Calafat; Thomas F Webster; Edward S Horton; Emily Oken
Journal:  Environ Int       Date:  2021-01-19       Impact factor: 9.621

4.  Biomonitoring of per- and polyfluoroalkyl substances in minority angler communities in central New York State.

Authors:  Wendy A Wattigney; Sanghamitra S Savadatti; Ming Liu; Marian Pavuk; Elizabeth Lewis-Michl; Kurunthachalam Kannan; Wei Wang; Henry Spliethoff; Lydia Marquez-Bravo; Syni-An Hwang
Journal:  Environ Res       Date:  2021-10-30       Impact factor: 6.498

5.  Development of a Gestational and Lactational Physiologically Based Pharmacokinetic (PBPK) Model for Perfluorooctane Sulfonate (PFOS) in Rats and Humans and Its Implications in the Derivation of Health-Based Toxicity Values.

Authors:  Wei-Chun Chou; Zhoumeng Lin
Journal:  Environ Health Perspect       Date:  2021-03-17       Impact factor: 9.031

6.  Can profiles of poly- and Perfluoroalkyl substances (PFASs) in human serum provide information on major exposure sources?

Authors:  Xindi C Hu; Clifton Dassuncao; Xianming Zhang; Philippe Grandjean; Pál Weihe; Glenys M Webster; Flemming Nielsen; Elsie M Sunderland
Journal:  Environ Health       Date:  2018-02-01       Impact factor: 5.984

Review 7.  Advancing per- and polyfluoroalkyl substances (PFAS) research: an overview of ATSDR and NCEH activities and recommendations.

Authors:  Rachel D Rogers; Christopher M Reh; Patrick Breysse
Journal:  J Expo Sci Environ Epidemiol       Date:  2021-04-01       Impact factor: 5.563

Review 8.  Why is elevation of serum cholesterol associated with exposure to perfluoroalkyl substances (PFAS) in humans? A workshop report on potential mechanisms.

Authors:  Melvin E Andersen; Bruno Hagenbuch; Udayan Apte; J Christopher Corton; Tony Fletcher; Christopher Lau; William L Roth; Bart Staels; Gloria L Vega; Harvey J Clewell; Matthew P Longnecker
Journal:  Toxicology       Date:  2021-07-08       Impact factor: 4.571

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.